Literature DB >> 24525640

The association of genetic polymorphisms in the κ-opioid receptor 1 gene with body weight, alcohol use, and withdrawal symptoms in patients with methadone maintenance.

Sheng-Chang Wang1, Hsiao-Hui Tsou, Ren-Hua Chung, Yao-Sheng Chang, Chiu-Ping Fang, Chia-Hui Chen, Ing-Kang Ho, Hsiang-Wei Kuo, Shu Chih Liu, Yu-Huei Shih, Hsiao-Yu Wu, Bo-Hau Huang, Keh-Ming Lin, Andrew C H Chen, Chin-Fu Hsiao, Yu-Li Liu.   

Abstract

Methadone is a synthetic opioid that binds to the κ-opioid receptor with a low affinity. This study tested the hypotheses that the genetic polymorphisms in the κ-opioid receptor 1 (OPRK1) gene region are associated with methadone treatment responses in a Taiwan methadone maintenance treatment (MMT) cohort. Seventeen single nucleotide polymorphisms (SNPs) in OPRK1 were selected and genotyped on DNA of 366 MMT patients. Six SNPs from rs7843965 to rs1051660 (intron 2 to exon 2) were significantly associated with body weight (P < 0.007). A haplotype of 4 SNPs rs7832417-rs16918853-rs702764-rs7817710 (exon 4 to intron 3) was associated with bone or joint aches (P ≤ 0.004) and with the amount of alcohol use (standard drinks per day; global P < 0.0001). The haplotype rs10958350-rs7016778-rs12675595 was associated with gooseflesh skin (global P < 0.0001), yawning (global P = 0.0001), and restlessness (global P < 0.0001) withdrawal symptoms. The findings suggest that genetic polymorphisms in OPRK1 were associated with the body weight, alcohol use, and opioid withdrawal symptoms in MMT patients.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24525640     DOI: 10.1097/JCP.0000000000000082

Source DB:  PubMed          Journal:  J Clin Psychopharmacol        ISSN: 0271-0749            Impact factor:   3.153


  15 in total

1.  Searching for evidence of genetic mediation of opioid withdrawal by opioid receptor gene polymorphisms.

Authors:  Jermaine D Jones; Rachel R Luba; Jonathan L Vogelman; Sandra D Comer
Journal:  Am J Addict       Date:  2015-12-21

Review 2.  Pharmacogenetics of Opioid Use Disorder Treatment.

Authors:  Richard C Crist; Toni-Kim Clarke; Wade H Berrettini
Journal:  CNS Drugs       Date:  2018-04       Impact factor: 5.749

Review 3.  Pharmacogenetics of Methadone Response.

Authors:  Francina Fonseca; Marta Torrens
Journal:  Mol Diagn Ther       Date:  2018-02       Impact factor: 4.074

Review 4.  Kappa opioid receptor signaling in the brain: Circuitry and implications for treatment.

Authors:  Nicole A Crowley; Thomas L Kash
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2015-01-12       Impact factor: 5.067

5.  Pharmacogenetics of Addiction Therapy.

Authors:  David P Graham; Mark J Harding; David A Nielsen
Journal:  Methods Mol Biol       Date:  2022

Review 6.  Endogenous opioid system: a promising target for future smoking cessation medications.

Authors:  Haval Norman; Manoranjan S D'Souza
Journal:  Psychopharmacology (Berl)       Date:  2017-03-11       Impact factor: 4.530

7.  Variations in opioid receptor genes in neonatal abstinence syndrome.

Authors:  Elisha M Wachman; Marie J Hayes; Richard Sherva; Mark S Brown; Jonathan M Davis; Lindsay A Farrer; David A Nielsen
Journal:  Drug Alcohol Depend       Date:  2015-07-08       Impact factor: 4.492

8.  Genetic polymorphisms in the opioid receptor delta 1 (OPRD1) gene are associated with methadone dose in methadone maintenance treatment for heroin dependence.

Authors:  Chiu-Ping Fang; Sheng-Chang Wang; Hsiao-Hui Tsou; Ren-Hua Chung; Ya-Ting Hsu; Shu Chih Liu; Hsiang-Wei Kuo; Tung-Hsia Liu; Andrew C H Chen; Yu-Li Liu
Journal:  J Hum Genet       Date:  2020-01-07       Impact factor: 3.172

9.  Clinical-genetic model predicts incident impulse control disorders in Parkinson's disease.

Authors:  Julia Kraemmer; Kara Smith; Daniel Weintraub; Vincent Guillemot; Mike A Nalls; Florence Cormier-Dequaire; Ivan Moszer; Alexis Brice; Andrew B Singleton; Jean-Christophe Corvol
Journal:  J Neurol Neurosurg Psychiatry       Date:  2016-04-13       Impact factor: 10.154

10.  Kappa Opioid Signaling at the Crossroads of Chronic Pain and Opioid Addiction.

Authors:  Catherine M Cahill; Lindsay Lueptow; Hannah Kim; Raj Shusharla; Amy Bishop; Christopher J Evans
Journal:  Handb Exp Pharmacol       Date:  2022
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.